Overview of Sanofi's Capital Structure
Sanofi, a prominent player in the global pharmaceutical field, offers key insights into its capital structure and shareholder rights. This includes comprehensive information regarding the total number of voting rights and shares. Understanding this information is essential as it reflects the company’s health and market performance.
Details on Voting Rights and Issued Shares
According to French regulations, companies must disclose significant shareholder information periodically. For Sanofi, the total issued shares as of the end of the year were 1,263,122,721. This figure plays a crucial role in determining the shareholder base's influence on company decisions.
Real Voting Rights
Real voting rights, which exclude treasury shares, stood at 1,413,130,110. This number indicates the actual equity held by shareholders that can influence corporate matters. The ability for stakeholders to have a say in company affairs is vital for maintaining a responsive corporate governance structure.
Theoretical Voting Rights
Including treasury shares, the theoretical number of voting rights reached 1,422,661,191. This broader measurement showcases the extent of influence available when all shares, including those that may be held and not currently voting, are taken into account.
Why This Information Matters
Understanding voting rights and the number of issued shares is integral for investors evaluating their stakes. Transparency in these numbers ensures that shareholders are well-informed about their voting power and overall influence within Sanofi. Such information can also impact stock performance and market perception among potential investors.
Additional Company Information
For further insights, stakeholders are encouraged to visit Sanofi’s official website. It contains detailed resources categorized under “Regulated Information in France,” where these disclosures are updated regularly. Keeping abreast of these changes allows investors to make informed choices regarding their investments in Sanofi.
Contacting Investor Relations
For inquiries or further information, interested parties can contact Sanofi’s Investor Relations Department. They provide a direct line to facilitate communication between the company and its shareholders. The email address for reaching out is investor.relations@sanofi.com. This open line supports transparency and ongoing dialogue with investors.
Frequently Asked Questions
What is the total number of issued shares for Sanofi?
The total number of issued shares for Sanofi is 1,263,122,721.
How many real voting rights does Sanofi have?
Sanofi has 1,413,130,110 real voting rights, excluding treasury shares.
What are theoretical voting rights?
Theoretical voting rights, including treasury shares, amount to 1,422,661,191 for Sanofi.
Why are voting rights important for shareholders?
Voting rights are essential as they allow shareholders to influence significant business decisions and corporate governance matters.
Where can I find more information about Sanofi’s shares?
More information can be found on Sanofi's official website under the section for Regulated Information in France.
